A preliminary randomized trial of the mechanical insufflator-exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis

• Published in: Amyotrophic lateral sclerosis and frontotemporal degeneration Vol. 16; no. 7-8; pp. 448 - 455
• Main Authors: Rafiq, Muhammad K., Bradburn, Michael, Proctor, Alison R., Billings, Catherine G., Bianchi, Stephen, McDermott, Christopher J., Shaw, Pamela J.
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 27-11-2015
• Subjects: Aged; Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - complications; Amyotrophic Lateral Sclerosis - mortality; Amyotrophic Lateral Sclerosis - physiopathology; Amyotrophic Lateral Sclerosis - therapy; Cough; cough assist; cough augmentation; exsufflation; Female; Humans; insufflation; Kaplan-Meier Estimate; lung volume recruitment; Male; manual breath-stacking technique; mechanical in-exsufflator; Middle Aged; Noninvasive Ventilation; Proportional Hazards Models; Respiratory Insufficiency - etiology; Respiratory Insufficiency - mortality; Respiratory Insufficiency - physiopathology; Respiratory Insufficiency - therapy; Respiratory Therapy - instrumentation; Respiratory Therapy - methods; Suction - instrumentation; Suction - methods; Survival Rate; Treatment Outcome; mechanical in-exsufflator; insufflation; exsufflation; lung volume recruitment; cough assist; manual breath-stacking technique; Amyotrophic lateral sclerosis; cough augmentation
• ISSN: 2167-8421; 2167-9223
• DOI: 10.3109/21678421.2015.1051992

A major problem faced by patients with amyotrophic lateral sclerosis (ALS) in respiratory failure is the inability to cough effectively. Forty eligible ALS patients were randomized to the breath-stacking technique using a lung volume recruitment bag (n = 21) or mechanical insufflator-exsufflator MI-E (n = 19) and followed up at three-monthly intervals for at least 12 months or until death. Results showed that there were 13 episodes of chest infection in the breath-stacking group and 19 episodes in the MI-E group (p = 0.92), requiring 90 and 95 days of antibiotics, respectively (p = 0.34). The mean duration of symptoms per chest infection was 6.9 days in the breath-stacking group and 3.9 days in MI-E group (p = 0.16). There were six episodes of hospitalization in each group (p = 0.64). The chance of hospitalization, in the event of a chest infection, was 0.46 in the breath-stacking group and 0.31 in MI-E group (p = 0.47). Median survival in the breath-stacking group was 535 days and 266 days in the MI-E group (p = 0.34). The QoL was maintained above 75% of baseline for a median of 329 days in the breath-stacking group and 205 days in the MI-E group (p = 0.41). In conclusion, lack of statistically significant differences due to sub-optimal power and confounders precludes a definitive conclusion with respect to the relative efficacy of one cough augmentation technique over the other. This study however, provides useful lessons and informative data, needed to strengthen the power calculation, inclusion criteria and randomization factors for a large scale definitive trial. Until such a definitive trial can be undertaken, we recommend the breath-stacking technique as a low-cost, first-line intervention for volume recruitment and cough augmentation in patients with ALS who meet the criteria for intervention with non-invasive ventilation.